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long-term outcomes and overall cost savings relative to meniscectomy, making it the 
dominant treatment strategy from a health-economic perspective.
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OBJECTIVES: Gout is the most common and progressive arthritic condition. Its sever-
ity is assumed to have implications for the humanistic and economic burden of 
the illness. The objective of this study is to examine the burden of gout between 
patients with and without tophi using electronic health records (EHR). METHODS: 
The Humedica EHR database was searched starting on January 1, 2008 through 
February 28, 2013 for patients having an initial gout diagnosis (ICD-9 274.xx) and 
a confirmatory gout diagnosis at least 30 days later. Deidentified patients with 
enrollment from 6-months pre/12-months post initial gout diagnosis and at least 
one serum uric acid (SUA) level were included in the study. Patients (n= 933) with a 
diagnosis of tophaceous gout (274.03, 274.81, and 274.82) during the 12-months post-
index period were compared to all other gout (non-tophaceous) patients (n= 45,512). 
Demographic characteristics and comorbidities, SUA levels, and use of colchicine 
for acute flares during the 12-months post-index period were compared using chi-
square tests. RESULTS: Gout patients with tophi were more likely to be female 
(p< 0.01) and have uncontrolled (SUA= 6-8) or severely uncontrolled (SUA = > 10) SUA 
(p< 0.0001) than patients without tophi. Colchicine use was higher in patients with 
tophi (p< .0001). There were significantly higher levels of cardiovascular comorbidities 
in the gout patients with tophi vs those without: hypertension (p< 0.05), myocardial 
infarction (p< 0.01), atherosclerosis (p< 0.0001), dyslipidemia (p< 0.0001), peripheral 
arterial disease (p< 0.0001), congestive heart failure (p< 0.0001), chronic heart disease 
(p< 0.0001), cardiomyopathy(p< 0.0001), ischemic and valvular heart disease (p< 0.0001) 
and left ventricular hypertrophy (p< 0.001). Gout patients with tophi had higher levels 
of chronic kidney disease, Stages 3-5, (p< 0.0001), osteoarthritis (p< 0.0001), rheuma-
toid arthritis (p< 0.0001). CONCLUSIONS: Gout patients with tophi had significantly 
greater burden of disease and greater frequency of comorbidities than those without. 
Preventing the development of tophi may reduce comorbidities and frequency of 
colchicine use and warrants further investigation.
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OBJECTIVES: Psoriatic arthritis (PsA) is an inflammatory arthritis associated with 
skin psoriasis. PsA causes swelling, stiffness and pain in joints, it may also affect 
the spine, ankles and wrists. It is also associated with decreased quality-of-life in 
its patients. Treatment of PsA includes both pharmacological and non-pharmaco-
logical treatments. The research aims to estimate the economic burden of PsA in 
Taiwan. METHODS: The National Health Insurance Research Database (NHIRD), 
a claims-based dataset encompassing 99% of Taiwan’s population, was applied. 
The database measures direct costs to the healthcare system and does not take 
into account indirect costs such as absenteeism or loss of productivity. We used a 
micro-costing approach for direct health care costs by estimating the quantities 
and prices of cost categories. Direct costs included surgeries, ward usage, medical 
devices and materials, lab tests, PUVA therapy and medications. The costs and 
quantities of the direct economic burden were calculated based on 2011 data of 
NHIRD. We identified PsA patients and a control cohort matched 1:4 on demographic 
and clinical covariates to calculate the incremental cost related to PsA. RESULTS: 
A total of 4,053 PsA patients were included in the database with incremental total 
direct cost of $13,282,615. This resulted in an average incremental direct cost of 
$3,277 per PsA patient. Direct costs were mostly influenced by medication costs 
($11,991,479; 90.28%), while lab tests ($576,403; 4.34%), PUVA therapy ($348,741; 
2.63%), surgery ($150,471; 1.13%), ward usage ($130,978; 0.99%) and medical devices/
materials ($84,543; 0.64%) made up the balance. Within medication costs, biologic 
and tablet disease-modifying anti-rheumatic drugs accounted for 45% and 22% 
of all medication costs, respectively. CONCLUSIONS: Our findings highlight the 
significant economic burden PsA places on Taiwan’s economy. The direct costs of 
PsA in Taiwan are driven by medication costs and lab tests. Efficient management 
of PsA could reduce the economic impact of the disease.
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OBJECTIVES: Rheumatoid Arthritis (RA) is a chronic inflammatory disease which 
destroys synovial joints and generates pain; RA could disable patients and could be 
the cause of premature death. Its prevalence for Chile has been estimated in 0.46% 
(IC 95% 0.24-0.8). Available drugs for treatment include conventional synthetic 
Disease-Modifying Antirheumatic Drugs (csDMARDs), biological therapies and a 
new oral janus kinase inhibitor drug approved for treatment after failure of csD-
MARDs: tofacitinib. The aim of this study is to determine the direct costs associ-
ated with available therapies after csDMARDs failure. METHODS: The analysis was 
made from third payer perspective with a time horizon of one year. Costs baskets 
were constructed, considering the costs of diagnosis, treatment and monitoring 
of the intervention and validated with rheumatologists. Drug costs were obtained 
from public tenders and official reports. Comparators were: tofacitinib (5mg twice/
OBJECTIVES: To assess the influence of different treatment schemes of post-stroke 
spasticity on societal costs in Russia. METHODS: Analytical model of decision-
making in Microsoft Excel 2013 was designed for assessing an influence of local 
standard therapy and different types of botulinum toxin (abobotulinumtoxinA, 
onabotulinumtoxinA, incobotulinumtoxinA) on the societal costs. Societal costs 
included: disability pensions, temporary disability benefit and GDP loss of due to 
loss of working force in case post-stroke spasticity. Disability assessment scale 
score was used as efficacy criteria. The main domains of this scale (0 – normal life, 
3 – full disability) were compared with Russian disability group system (1st group 
of disability – severe grade, 3d group – mild grade). According to the information 
retrieval using Ministry of trade and social development database and clinical tri-
als data it was found that in 2014 out of 287,314 people with post-stroke spastic-
ity there were 12,7% disabled people of 1st grade, 32,7% of 2nd one and 34,6% of 
3d one. 20% of people have no disability group. For reference, accepted exchange 
rate was 1 US$ = 60,29 RUB. RESULTS: Therapy with abobotulinumtoxinA allows to 
decrease disability level with 16%-efficacy, therapy with onabotulinumtoxinA with 
12,6 %-efficacy, standard therapy with 3,3%-efficacy. Consequently, societal costs 
economy for whole population of post-stroke spasticity patients for one year is US$ 
378,97 million higher compared with standard therapy, US$ 119,21 million higher 
compared with onabotulinumtoxinA treatment scheme, and US$ 129,47 million 
higher compared with incobotulinumtoxinA treatment scheme. CONCLUSIONS: 
AbobotulinumtoxinA treatment scheme shows more prominent decrease of disabil-
ity level in post-stroke spasticity patients in Russia and allows to decrease societal 
costs to a greater extent compared with other alternatives. That fact makes abobo-
tulinumtoxinA more beneficial from the societal costs perspective compared with 
other treatment schemes.
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OBJECTIVES: The full economic impact of brand to generic switching within OA 
has not been well studied. The purpose of this study was to measure switch rates 
from the branded COX-2 inhibitor Celebrex (celecoxib) to generic non-steroidal anti-
inflammatory drugs (NSAIDs) and compare economic outcomes between switched 
and persistent patients with OA. METHODS: This retrospective claims analysis used 
MarketScan®2009 to 2013 data to extract a cohort of incident adult OA (ICD-9-CM: 715.
xx) patients prescribed with Celebrex. Patients included had 12-month continuous 
enrollment before (pre-index) and ≥ 6 months after their first (index) Celebrex claim 
and had ≥ 2 Celebrex claims. Persistence was measured as time to the first prescrip-
tion gap of ≥ 30 days; treatment switch to generic NSAIDs required a fill for generic 
NSAIDs within 30 days of discontinuing Celebrex. Annualized healthcare resource 
utilization (HCRU) and direct costs were compared descriptively between patients 
switched to generic NSAIDs and persistent patients within propensity score matched 
cohorts. RESULTS: The 65,530 included patients had mean±SD age 61±11.9 years 
and were 62.5% female. By end of follow-up, 6,783 (10.35%) patients were persistent 
on Celebrex. The majority of patients (54,554, 83.3%) discontinued Celebrex without 
switching and 3,475 (5.3%) switched to generic NSAIDs (median time to switch or 
discontinuation was 2.96 months). After matching (N= 3,298 per cohort), persistent 
users had less HCRU and significantly lower mean total costs ($23,949 vs $20,378, P < 
.001) compared to switched patients. Mean OA-related costs were similar for persis-
tent vs switched patients ($5,755 vs $5,910, P= 0.63), with persistent patients having 
higher mean drug costs ($2,693 vs. $1,098, P< .001) but lower mean inpatient ($2,370 vs 
$3,622, P< .001) and outpatient costs ($848 vs $1,035, P< .001). CONCLUSIONS: Despite 
lower drug costs, switching from Celebrex to generic NSAIDs was associated with 
greater inpatient and outpatient visits, leading to higher overall costs for OA patients.
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OBJECTIVES: Meniscal tears are the most common knee condition requiring surgery, 
and represent a substantial disease burden with long-term clinical and cost implica-
tions. Research performed over the last two decades has shed light on the success 
rates of the two primary treatment strategies—partial meniscectomy and meniscus 
repair. However, only limited information is available about the long-term costs and 
effects of these strategies. Our objective was to assess the long-term cost-effective-
ness of meniscus repair compared to meniscectomy. METHODS: We constructed 
a decision-analytic Markov disease progression model, taking into account index 
strategy-specific failure rates as well as treatment-specific probabilities for the devel-
opment of osteoarthritis (OA) and subsequent total knee replacement (TKR). Failure 
rates and OA incidence were derived from a review of controlled and uncontrolled 
studies as well as recent meta-analyses. Costs were derived from current 2014 U.S. 
national average reimbursement amounts and the published literature. We computed 
the 20-year incremental cost-effectiveness ratio (ICER) and relative event risks in a 
cohort of 38 year-old patients, 21% of whom were female. RESULTS: Over the 20 
year horizon, meniscus repair was associated with an gradual increase in discounted 
QALYs from 12.84 to 12.99 compared to meniscectomy, at overall discounted savings 
of $2,598, making it the dominant index procedure strategy. While the meniscus 
repair strategy was associated with an increased failure rate (RR of 6.12), it led to 
substantial reductions in OA and TKR incidence (16.0% vs. 29.4% and 8.5% vs. 16.1%, 
respectively). Clinical benefit and cost-effectiveness further improved with longer-
follow-up. CONCLUSIONS: Our model-based projection suggests that meniscus 
repair, despite substantially higher initial failure rates, is associated with improved 
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OBJECTIVES: To determine the demographic distribution and health care burden of 
patients diagnosed with rheumatoid arthritis (RA) using Medicare fee-for-service 
(FFS) data. METHODS: A retrospective analysis was performed using the 100% 
Medicare FFS datasets from October 1, 2008 through December 31, 2012. Patients 
diagnosed with RA were identified using International Classification of Diseases, 
9th Revision, Clinical Modification diagnosis code 714, and the first diagnosis date 
was designated as the index date. All patients were required to have continuous 
medical and pharmacy benefits 1 year pre- (baseline period) and post-index date 
(follow-up period). Health care resource utilization and costs during the baseline and 
follow-up periods were calculated. RESULTS: Using Medicare FFS data, 112,550 RA 
patients were identified. The average age at diagnosis was 76 years, and 72.54% of 
patients were women and 83.94% were white. The most common baseline comor-
bidities were diabetes (35.48%), followed by chronic obstructive pulmonary disease 
(30.83%) and cerebrovascular disease (21.50%). During the follow-up period, 66.35% 
of patients had inpatient admissions, 49.01% had emergency room visits, 87.93% 
had outpatient office visits, 87.93% had outpatient visits and 61.67% had pharmacy 
visits and costs were, on average, $26,510, $256, $4,204, $4,460 and $6,249, respec-
tively. The average total costs incurred by RA patients were $37,219. The five most 
commonly-prescribed medications prescribed to treat RA were prednisone (3.40%), 
levothyroxine sodium (2.63%), hydrocodone bit/acetaminophen (2.39%), furosemide 
(2.13%) and omeprazole (2.13%). CONCLUSIONS: RA patient demographic distri-
butions and RA-related health care cost information was obtained and the most 
commonly prescribed medications to treat RA were identified.
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OBJECTIVES: This study evaluated the comparative risk of transfusion, in-
hospital complications, and incremental total hospitalization costs of primary 
unilateral, simultaneous bilateral, and revision total knee arthroplasty (TKA) proce-
dures. METHODS: Using the Premier Database from 1/1/2008 – 6/30/2014, we identi-
fied adults 18+ years old who underwent primary unilateral, simultaneous bilateral, 
or revision TKA procedure. Patients with multiple orthopedic procedures during the 
hospitalization, fracture diagnoses, and oncologic diagnosis were excluded. Logistic 
regressions – controlling for age, sex, region, hospital size, academic status, payor, 
procedure year, obesity diagnosis, and Charlson Score – were used to determine the 
risk of autologous or allogeneic blood transfusion. Generalized linear models (GLM) 
– controlling for the same factors – predicted the incremental total hospitalization 
cost associated with transfusion. RESULTS: 513,558 primary (mean age, 66; 37% 
male), 33,977 bilateral (mean age, 63, 43% male), and 32,494 revision (mean age 65, 
41% male) TKA patients met selection criteria. The overall percentage transfused 
was 14.1%, 36.3%, and 20.0%, respectively. Regressions indicated the following fac-
tors were significantly associated with higher transfusion risk: age > 65, females, 
residing in the Northeast, large hospitals, and higher Charlson Score. Though risk 
of transfusion decreased over the study period, the highest comorbidity (Charlson 
3+) patients were at 2.27 (primary), 1.88 (bilateral), and 2.44 (revision) greater odds 
of transfusion vs healthy controls. Unadjusted total hospitalization costs were 
$17,685, $28,557, and $26,972 for each procedure, respectively. GLM results showed 
an incremental total hospitalization cost among those with transfusion vs. without 
of $2,840, $4,985, and $9,267, respectively. CONCLUSIONS: Transfusion risk, while 
decreasing over recent years, is still a burden in select patient populations and 
procedures. The incremental cost of requiring a transfusion is significant, including 
not only direct costs of blood administration but staff time and increased hospital 
resource use. Strategies to decrease transfusion risk among select patient popula-
tions are warranted.
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OBJECTIVES: This study evaluated the correlation between patient comorbid-
ity status and total hospitalization length of stay (LOS) and cost for total knee 
arthroplasty (TKA), total hip arthroplasty (THA), and one to three level lumbar 
spinal fusion procedures. METHODS: Using the Premier Database from 1/1/2008 
– 6/30/2014, we identified adults 18+ years old with a primary procedure of TKA, 
THA, or spinal fusion. Patients with multiple orthopedic procedures during the 
hospitalization, fracture diagnoses, and revision procedures were excluded. 
Mean hospital length of stay (LOS) was compared by Charlson Score with ANOVA. 
Generalized linear models (GLM) – controlling for age, sex, region, hospital size, 
academic status, payor, and procedure year – predicted the incremental total hos-
pitalization cost among the sickest patients (Charlson ≥ 3) vs healthy controls 
(Charlson zero). RESULTS: 536,582 TKA (mean age, 66; 37% male), 275,953 THA 
(mean age, 64, 45% male), and 177,493 fusion (mean age 57, 44% male) patients met 
selection criteria. Mean ± SD Charlson Scores were 0.67 ± 0.97, 0.57 ± 0.95, and 0.57 
± 0.92, and the percent with a Charlson of ≥ 3 were 5.4%, 4.7%, and 4.3%. Mean LOS 
increased by 0.9 ± 1.5, 1.4 ± 2.3, and 2.3 ± 3.8 days for patients with a Charlson of ≥ 
3 vs zero for each procedure, respectively. Unadjusted total hospitalization costs 
were $17,512, $18,915, and $32,932, respectively. GLM results showed an incre-
mental total hospitalization cost of a Charlson Score of ≥ 3 vs. 0 of $2,211, $3,041, 
and $3,922 for each procedure, respectively. CONCLUSIONS: While a relatively 
small proportion of all patients undergoing elective orthopedic procedures, the 
sickest patients (Charlson ≥ 3) were associated with a significant hospitalization 
cost burden. With patient comorbidity burden growing nationally, this study war-
rants further examination of improved standards of care for comorbid patients 
undergoing elective orthopedic procedures.
day); abatacept (750 mg weeks 0-2-4 and then every 4 weeks); adalimumab (40mg 
every two weeks); certolizumab (400mg at weeks 0-2, 4 and then 200mg every 4 
weeks); etanercept (50mg/week); golimumab (50mg/month); infliximab (3mg/kg 
weeks 0-2-6 and then every 8 weeks); rituximab (1000mg weeks 0-2 and then 24 
weeks after); tocilizumab 8mg/kg every 4 weeks). Dosage information was taken 
from Instituto de Salud Publica de Chile, an average weight of 70kg was consid-
ered for those drugs whose dose depends of weight. Results are expressed in 
2014USD (exchange rate US$1 = CLP$600) RESULTS: In a time horizon of one year, 
the costs associated with the RA treatment were in average: US$93.83 diagnosis, 
US$269.19 monitoring, US$59.73 concomitant drugs. The annual cost of RA treat-
ment with available drugs after conventional csDMARDs failure was estimated 
between US$9,378.4 (tofacitinib) and US$18,368.9 (abatacept) as highest and low-
est options. CONCLUSIONS: For the analyzed scenario, tofacitinib is the option 
with lower costs, generating savings in comparison with the biological therapies 
available for RA after csDMARDs failure.
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OBJECTIVES: Bone loss and fractures following initiation of androgen deprivation 
therapy (ADT) result in excess healthcare costs. There is limited information regard-
ing the extent to which these costs depend on the patient’s comorbidity profile. We 
examined the influence of baseline comorbidity status on the incremental cost of 
fractures in older men with non-metastatic PCa and treated with ADT. METHODS: 
Using linked Surveillance, Epidemiology, and End Results & Medicare data, we iden-
tified men aged 66+ with incident non-metastatic PCa diagnosed during 2000-2005 
and treated with ADT. Patients were followed until death or up to 5 years after ADT 
initiation. Total direct medical costs, in 2010 dollars, were calculated for each month. 
To account for censoring, monthly costs were weighted by the inverse probability 
of being uncensored. Partitioned weighted least squares regression models were 
estimated to determine the incremental cost of fractures for subgroups defined 
by the baseline Charlson Comorbidity Index (CCI). RESULTS: Application of study 
inclusion criteria resulted in 30,904 men with non-metastatic PCa (median age: 76 
years), of whom 57% had 5 years of follow-up, 28% died, and 15% were censored. 
The mean (interquartile range) unadjusted 5-year total cost was $77,244 ($35,366 
- $97,087), and was higher (p< 0.01) for men with baseline congestive heart failure, 
chronic renal failure, and diabetes with complications. During follow-up, 6,779 men 
(22%) experienced a fracture, and the mean (median) time from ADT initiation to 
first fracture was 25.1 (22.8) months. The adjusted incremental cost of fractures was 
$33,650 on average and varied by baseline CCI as follows: $31,800 among patients 
with CCI= 0; $34,320 among patients with CCI= 1; and $46,678 among patients with 
CCI= 2 or higher. CONCLUSIONS: Among older men with PCa treated with ADT, the 
incremental cost of fractures was highest among those with greater comorbidity 
burden.
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OBJECTIVES: To investigate the health care cost burden and demographic distribution 
of patients diagnosed with psoriatic arthritis (PSA) in the Medicare fee-for-service 
(FFS) Dataset. METHODS: A retrospective database analysis was performed using 
the 100% Medicare FFS Datasets from October 1, 2008 through December 31, 2012. 
Patients diagnosed with PSA were identified using International Classification of 
Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis code 696.0, and 
the index date was the date of the initial diagnosis. All patients were required to have 
continuous medical and pharmacy benefits 1-year pre- and post-index date. Health 
care costs and utilization during the baseline (1 year before the diagnosis date) and 
follow-up (1 year after the diagnosis date) periods were calculated. RESULTS: Using 
the aforementioned criteria, 11,324 PSA patients were identified. The average age 
at diagnosis was 74 years, 66.10% of patients were women and almost 92.36% were 
white. The majority of patients resided in the South U.S. region (39.01%). Diabetes 
(33.84%), chronic obstructive pulmonary disease (29.04%) and cerebrovascular disease 
(17.36%) were the main comorbidities observed during the baseline period. During 
the follow-up period, 62.96% of patients had inpatient admissions, 47.29% had emer-
gency room visits, 91.67% had outpatient office visits, 91.67% had outpatient visits 
and 58.03% had pharmacy visits, costing, on average, $23,960, $237, $5,015, $5,252 
and $7,335, respectively. The average total cost of PSA patients was $36,548. The five 
most commonly prescribed medications for PSA were methotrexate sodium (4.54%), 
prednisone (3.37%), levothyroxine sodium (2.59%), hydrocodone bit/acetaminophen 
(2.43%) and simvastatin (2.11%). CONCLUSIONS: PSA patient demographic and health 
care cost information was obtained and the most commonly prescribed PSA medica-
tions were identified.
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